Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zimmer Biomet HoldingsXSWX:ZBH +1.23%72 3-Year EPS without NRI Growth Rate is 6.00% as of Jun. 2026, which is 24% below its 10-year median of 7.90. GuruFocus rates XSWX:ZBH with a GF Score™ of 72/100 and a GF Value™ of CHF101.60. The stock has 2 warning signs investors should review. Among 660 Medical Devices & Instruments companies, Zimmer Biomet Holdings ranks worse than 52.88% on this metric.
During the past 12 months, Zimmer Biomet Holdings's average EPS without NRI Growth Rate was 6.90% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 6.00% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 5.60% per year.
During the past 10 years, the average EPS without NRI Growth Rate was -0.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Zimmer Biomet Holdings was 46.70% per year. The lowest was -11.00% per year. And the median was 7.90% per year.
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Zimmer Biomet Holdings 3-Year EPS without NRI Growth Rate Related Terms
XSWX:ZBH vs STE, PEN, GMED: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Zimmer Biomet Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zimmer Biomet Holdings 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Zimmer Biomet Holdings's 3-Year EPS without NRI Growth Rate falls into.
Zimmer Biomet Holdings 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 6.00% mean?
Zimmer Biomet Holdings (XSWX:ZBH) has a 3-Year EPS without NRI Growth Rate of 6.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Zimmer Biomet Holdings and its competitors. This is 24% below median its historical median of 7.90. According to the industry distribution chart, Zimmer Biomet Holdings ranks #349 out of 660 companies in the Medical Devices & Instruments industry, placing it in the top 52.9%.
Is Zimmer Biomet Holdings' 3-Year EPS without NRI Growth Rate too high?
Zimmer Biomet Holdings' current 3-Year EPS without NRI Growth Rate of 6.00% is 24% below median its 10-year median of 7.90. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 7.75. Zimmer Biomet Holdings' value of 6.00% is 22.6% below this industry median. Based on the distribution chart, Zimmer Biomet Holdings ranks #349 out of 660 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Zimmer Biomet Holdings has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' 3-Year EPS without NRI Growth Rate compare to STE and PEN?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #349 out of 660 companies for 3-Year EPS without NRI Growth Rate. This places Zimmer Biomet Holdings in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 7.75. Zimmer Biomet Holdings' value of 6.00% is 22.6% below this benchmark. While the company's 10-year median is 7.90 vs. the industry median of 7.75, Zimmer Biomet Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 7.75, based on 660 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zimmer Biomet Holdings's current 3-Year EPS without NRI Growth Rate of 6.00% is 22.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Zimmer Biomet Holdings and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 7.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zimmer Biomet Holdings's current 3-Year EPS without NRI Growth Rate is 6.00%, which is 24% below median its own 10-year median of 7.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Zimmer Biomet Holdings (XSWX:ZBH) has a current 3-Year EPS without NRI Growth Rate of 6.00%. The stock's GF Value™ is CHF101.60, compared to a current price of CHF82.00 — trading 19.3% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 6.00%, which is 24% below median its 10-year median of 7.90 and 22.6% below the Medical Devices & Instruments industry median of 7.75. Zimmer Biomet Holdings' overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current 3-Year EPS without NRI Growth Rate is 6.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?
Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued.
The current stock price of CHF82.00 is trading 19.3% below its estimated GF Value™ of CHF101.60.
Key valuation signals for XSWX:ZBH:
3-Year EPS without NRI Growth Rate: 6.00% (24% below median its 10-year median of 7.90)
GF Value™: CHF101.60 vs. price of CHF82.00 (19.3% below fair value)
Industry Position: 22.6% below the Medical Devices & Instruments median (#349 of 660)
No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
72GF Score
Get the complete analysis for XSWX:ZBH
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZBH has been successfully added to your 
